Cybin (TSE:CYBN) has released an update.
Cybin Inc., a clinical-stage neuropsychiatry company, is poised to launch a global Phase 3 pivotal program for its CYB003 treatment for Major Depressive Disorder. The company has bolstered its clinical team with key appointments including Dr. Mirza Rahman and Dr. Marcelo Gutierrez, alongside a host of other experienced professionals to support upcoming trials across 12 countries.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.